Damora Therapeutics is a biotechnology company based in Massachusetts that evolved from Galecto, Inc. after acquiring the private company Damora Therapeutics and adopting its name. The rebrand marked a clear shift in identity toward a focused blood-disorders platform built around targeted therapies for mutant calreticulin-driven diseases.
The company’s core business is developing disease-modifying treatments for mutant calreticulin-driven myeloproliferative neoplasms, a group of blood disorders that includes essential thrombocythemia and myelofibrosis. Rather than pursuing a broad range of unrelated drug categories, Damora is centered on biologic therapies designed to target the underlying drivers of these diseases more directly.
Its pipeline is built around DMR-001 as the lead program, along with DMR-002 and DMR-003, giving the company a concentrated portfolio within the same disease area. This makes Damora a specialist biotech company whose strategy is based on advancing a tightly connected set of programs instead of operating as a diversified pharmaceutical business.
Damora has its sights focus on mutant calreticulin-driven blood disorders, an area where it argues current treatment options do not directly address the root cause of disease. The company is positioning itself around highly targeted biologics, a focused hematology pipeline, and the resources to push its lead candidates through development.